Alzheimer's Drug Getting Label Revision, Biogen Says
The U.S. Food and Drug Administration has decided to rein in the recommended patient population for Biogen's Alzheimer's treatment aducanumab, the company said Thursday, a move that came about a month after...To view the full article, register now.
Already a subscriber? Click here to view full article